Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 79996 for:    subjects

Definition and Validation of Normative Data of EndoFLIP™ Measurements in Healthy Subjects (RUBY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03831724
Recruitment Status : Not yet recruiting
First Posted : February 6, 2019
Last Update Posted : February 6, 2019
Sponsor:
Information provided by (Responsible Party):
Medtronic - MITG

Brief Summary:

Multicenter, Prospective, Non-Randomized clinical trial to define and validate normative data of EGJ-distensibility measurements and contractile patterns in healthy subjects.

Asymptomatic subjects will be enrolled at up to 7 clinical sites in the United States.

Subjects who meet inclusion and no exclusion criteria and are deemed asymptomatic will be eligible for study enrollment.

The procedure visit/s will consist of the following procedures: High resolution manometry (HRM), esophagogastroduodenoscopy (EGD), endolumenal functional lumen imaging probe (EndoFLIP) and a Bravo procedure.

A post procedure follow-up phone call will be conducted within 5-9 days of completing all procedures.

HRM, EGD, and Bravo procedures are performed to evaluate subjects as normal in addition to being asymptomatic. Abnormal results in one or more of the procedures identifies the subject as unhealthy and the subject will be withdrawn from the study.

The expected duration of subject's participation in the study is up to 70 days (up to 30 days from screening to HRM, up to 30 days to complete EGD, EndoFLIP and Bravo, plus 5-9 days for follow up call).

Enrollment duration - up to 1 year


Condition or disease Intervention/treatment Phase
Healthy Subjects Device: EndoFLIP™ System with FLIP Topography Module Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Definition and Validation of Normative Data of EndoFLIP™ Measurements in Healthy Subjects ("RUBY Study")
Estimated Study Start Date : July 2019
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : May 2020

Arm Intervention/treatment
Experimental: EndoFLIP™ System
Device interventions included in this arm: HRM, EGD including biopsies, EndoFLIP and Bravo
Device: EndoFLIP™ System with FLIP Topography Module
The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.




Primary Outcome Measures :
  1. Define and validate normative data of esophago-gastric junction -distensibility index (EGJ-DI) measurements at 60mL in healthy subjects [ Time Frame: 70 days ]
    Median, 25% and 75% percentile for EGJ-DI measurements at 60mL balloon fill volume


Secondary Outcome Measures :
  1. To define and validate normative data for an EGJ-DI at different balloon fill volumes within the same subject [ Time Frame: 70 days ]
    Mean and median EGJ-DI at different balloon fill volumes of the same subject

  2. To define and validate normative data for a maximum restrictive EGJ diameter at different balloon fill volumes within the same subject [ Time Frame: 70 days ]
    Mean and median maximum restrictive EGJ diameter at different balloon fill volumes of the same subject

  3. To define and validate normative data of a distal esophageal body diameter at different balloon fill volumes within the same subject [ Time Frame: 70 days ]
    Mean and median distal esophageal body diameter at different balloon fill volumes of the same subject

  4. To define and validate normative data of contractile patterns at different balloon fill volumes within the same subject [ Time Frame: 70 days ]
    • Presence of Repetitive antegrade contractions (RACs) and number of antegrade contractions at different balloon fill volumes of the same subject
    • Presence of Repetitive Retrograde Contractions (RRCs) and number of retrograde contractions at different balloon fill volumes of the same subject



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male or female ages 18-75 years.
  2. The subject has the ability to give informed consent.
  3. The subject has the ability to undergo sedation, as assessed and determined by the treating physician or the anesthesiologist.
  4. BMI range of 18-30 kg/m2.
  5. Asymptomatic subjects as assessed by gastro-esophageal reflux disease questionnaire (GERDQ) negative score of less than 8 points (GERDQ <8) and brief esophageal dysphagia questionnaire (BEDQ) negative score of 0 points (BEDQ score=0), as assessed and determined by treating physician.

Exclusion Criteria:

  1. Subject has known or suspected major gastrointestinal motility disorders including but not limited to major esophageal motility disorders, EGJ outflow obstruction and delayed gastric emptying.
  2. Subject has dysphagia or any swallowing disorder.
  3. Subject has an inability to tolerate nasal intubation.
  4. Subject has a known or suspected bleeding diathesis.
  5. Subject with known or suspected Gastroesophageal Reflux Disease (GERD), or subject has symptoms of GERD.
  6. The subject has a known or suspected esophageal disease or disorder such as eosinophilic esophagitis (EOE), Barretts esophagus, severe esophagitis, upper GI bleeding or esophageal varices.
  7. Subject is known or is suspected to suffer from an esophageal stricture or obstruction.
  8. Subject has a hiatal hernia.
  9. Subject with medical comorbidities such as diabetes, hypertension hyper/hypothyroidism, or chronic obstructive pulmonary disease (COPD)
  10. Subject with a diagnosed autoimmune disease.
  11. Subject who has undergone prior upper GI surgery or interventions such as esophageal myotomy, fundoplication, dilatation or stent.
  12. Subject has a history of any malignancy.
  13. Subject has a history of any seizure disorder.
  14. Subject has a history of an eating disorder/s.
  15. Subject has an active history of nicotine use, cannabis use or alcohol abuse (as defined by: greater than 14 drinks/week or 4 drinks/day for men, 7 drinks/week or 3 drinks/day for women. A standard drink is defined as 12 oz of beer, 5 oz of wine, or 1.5 oz of liquor). Subject has used any tobacco, nicotine or cannabis products in the last 6 months or has abused alcohol in the last 6 months.
  16. Subject taking or prescribed or over-the-counter any acid suppressant medications (for example proton-pump inhibitors), any medication that treats reflux or heartburn symptoms (for example Tums and Maalox), any anticoagulant medications, any opiate medication or medication with known impact on GI motility.
  17. Subject has any allergy or other contraindication to the device components or to study medication used prior and/or during the procedure.
  18. Subject has a known sensitivity or allergy to nickel or other heavy metals.
  19. Subject has any condition, which according to the investigators judgment, precludes compliance with study and/or device instructions.
  20. Females who are pregnant or nursing at the time of screening and/or during the study period or are sexually active and of child bearing potential without medically acceptable methods of contraception.
  21. Subject who has a cardiac pacemaker or implantable cardiac defibrillator.
  22. Subject who has a general contraindication for upper endoscopy.
  23. Subject who is currently participating in another clinical study (investigational drug or device).
  24. Subject who is considered to be part of a vulnerable population (e.g. prisoners or those without sufficient mental capacity).
  25. Medtronic employees.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03831724


Contacts
Layout table for location contacts
Contact: Mirit Argov, PhD 972-49097879 mirit.argov@medtronic.com
Contact: Roni Pizem, MSc. 972-732501585 roni.pizem@medtronic.com

Sponsors and Collaborators
Medtronic - MITG
Investigators
Layout table for investigator information
Principal Investigator: Rena Yadlapati, MD University of Colorado, Denver

Layout table for additonal information
Responsible Party: Medtronic - MITG
ClinicalTrials.gov Identifier: NCT03831724     History of Changes
Other Study ID Numbers: MDT18047
First Posted: February 6, 2019    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No